Table 7 Effect of Oxaliplatin, free CDA and CDA-Dextran conjugates on the survival time (percentage increase in life span (ILS) and T/C % (treated vs. EAC control), EAC solid tumor weight and volume and activity of Caspase-independent apoptotic markers (PARP-1 and AIF). All values are presented as mean ± SEM. Statistical analysis was performed by one-way ANOVA (F-test). Statistical significance was defined as a p-value ≤0.05 indicating significant difference. Treated groups versus EAC positive control group, * P < 0.05. Ns, refers to non significant
Parameters | Positive control (EAC bearing) without any treatments | EAC + Oxaliplatin | EAC + Free CDA | EAC + CDA-Dextran |
|---|---|---|---|---|
ILS% | _ | 39.47 | 65.78 | 78.94 |
T/C% | _ | 139.47 | 165.78 | 178.94 |
EAC solid tumor weight (g) | 1.65 ± 0.15 | 1.45 ± 0.25 | 1.4 ± 0.16 | 1.3 ± 0.33 |
EAC tumor volume (mm3) | 2.67 ± 0.26 | 1.9 ± 0.49 | 1.48 ± 0.70 | 1.43 ± 0.07 |
PARP-1(pg/mg protein) | 325 ± 26.13 | 740.3 ± 61.68ns | 808.7 ± 12.33* | 1549 ± 134.5* |
AIF (pg/mg protein) | 57 ± 3.05 | 170 ± 6.93 ns | 257.3 ± 6.17* | 406.7 ± 45.96* |